Therapy in diabetic dyslipidemia
1Department of Pharmacology, VIPER, Tumkur, Karnataka, India.
Introduction:
Diabetics have an increased cardiovascular risk. This risk gets exaggerated by lipid abnormalities additionally. Diabetics have an increased propensity to develop dyslipidemia. Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride and low-density lipoprotein levels, decreased high-density lipoprotein levels.
Materials And Methods:
From the pilot study, a potent dose of saroglitazar and gemfibrozil was selected for this study. In this study, the experimental rats were divided into five groups of six animals in each group.
Results:
Combination therapy shows a decrease in lipid profile, atherogenic index, histopathological studies of different organs, and insulin levels compared to individual drugs and shows better therapeutic efficacy.
Conclusion:
Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors
Peripheral Artery Disease III: Interprofessional Care


